If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
207
results.
Updated on
14/10/2025 [06:50:00]
Results 50 to 75 of 207
Absstract of: WO2025212695A1
A rapid and cost-effective bacilli enrichment technology is provided that combines magnetic nanotechnologies with bacteriophage. The bacteriophage provides recognition functionality, while the magnetic nanocrystal clusters have excellent separation efficiency. Using portable and inexpensive devices, one can achieve rapid, point-of-care detection of tuberculosis, Non-Tuberculosis Mycobacterium (NTM) and urinary tract infection (UTI) in clinically relevant matrices, including sputum, urine, and blood, with a detection limit of 500 cfu/mL for BCG within 35 min. Excellent potential for clinical tuberculosis diagnostics in resource-limited settings is demonstrated.
Absstract of: WO2025212607A1
The present disclosure relates to pharmaceutical compositions for editing genes that can be administered through inhalation, such as via nebulization. In particular, these compositions contain β-sitosterol instead of other sterols or steroids. These compositions may show improved gene editing performance with fewer editing errors and/or improved aerosolization compared to lipid nanoparticles with cholesterol.
Absstract of: WO2025212557A1
Described herein is a conjugate having the formula of: A(L-I)x; wherein: A is a targeting moiety; L is a covalent linker; I is an Aurora kinase inhibitor; and x is a number of Aurora kinase inhibitors per targeting moiety, and can be an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, and fractional integers in between, and their use in treating and/or imaging a cancer or tumor or inflammation. The targeting moiety can include a targeting antibody, a fragment of a targeting antibody, an antibody-like structure, a nanoparticle drug delivery platform, a target-specific small molecule, a macromolecule, a peptide, and a peptide fragment.
Absstract of: WO2025211732A1
The present invention relates to lipid nanoparticles comprising ginsenoside or a derivative thereof, and use thereof, and, specifically, to: lipid nanoparticles containing vegetable ginsenoside or a derivative thereof included in ginseng or red ginseng, instead of animal cholesterol for the delivery of therapeutic or vaccine nucleic acids; gene-inorganic nanoparticles in which the corresponding lipid nanoparticles are encapsulated, and a preparation method therefor; and a nucleic acid delivery composition comprising same.
Absstract of: WO2025211353A1
Provided is a sheet exhibiting high drug delivery efficiency to the posterior part of the eye and excellent retentivity, which could not be achieved with a conventional method. The present invention provides a sheet containing nanofibers including a water-soluble polymer (A), wherein the water-soluble polymer (A) contains at least one selected from the group consisting of a polyvinyl alcohol-based resin, a hydroxyalkyl cellulose, and a polyethylene oxide; and the sheet comes into contact with at least one selected from the group consisting of the cornea, conjunctiva, and sclera, and maintains 50% or more of the mass after being immersed in phosphate-buffered saline at 37°C for 1 minute.
Absstract of: WO2025210606A1
A treatment for patients with GRIN disorder comprises overexpressing a GRIN1 gene without disrupting the genome and regardless of the type of mutation.
Absstract of: WO2025209612A1
The present invention relates to the modification of the surface of a silk-screen-printed carbon electrode by means of zinc oxide nanoparticles in the presence of carboxymethyl cellulose (ZnO-2), obtained using a new synthesis method. The ZnO-2 compound is selective and sensitive for the detection of hydrogen peroxide, and allows the adsorption of biomolecules, as well as electrochemical measurement in biosensors for the quantification of different analytes of diagnostic interest.
Absstract of: WO2025209535A1
Provided herein are compositions and associated methods for CH-based nano-carriers for therapeutic agents and their applications, a multi-step method for the synthesis of the pharmacologically stable and multifunctional CH-based nano-carriers, effectively carrying therapeutic or theranostic radioactive metal isotope, anionic immunotherapeutic agent, or other anionic therapeutic agents used as therapeutic drugs, including the one of "combined radio-and adjuvant immuno-therapy" for cancer treatment.
Absstract of: WO2025209581A1
Disclosed are a nitrogen-containing chain compound, a preparation method, a composition comprising the compound, and a use. Specifically, disclosed is a compound I or a pharmaceutically acceptable salt thereof. An LNP formulation prepared from the nitrogen-containing chain compound has relatively uniform nanoparticle size, high encapsulation efficiency, and high in-vivo expression activity.
Absstract of: WO2025209444A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt, isomer, isotope compound or solvate of the compound represented by formula (I). The present invention also provides a lipid nanoparticle comprising the compound represented by formula I or the pharmaceutically acceptable salt, isomer, isotope compound or solvate of the compound represented by formula I. The lipid nanoparticle can be used for nucleic acid delivery and has high organ targeting efficiency.
Absstract of: US2025312411A1
Pharmaceutical compositions and methods provide treatment of solid tumors based on simultaneously preventing the development and spread of multi-drug resistance (MDR) and a metastatic phenotype. This technology operates through the inhibition of two types of intercellular communication within the tumor microenvironment—tunneling nanotubes and extracellular vesicles, both of which promote the spread of MDR. Nanoparticle delivery of both an inhibitor of tunnelling nanotubes and an inhibitor of extracellular vesicle release work synergistically to trap and improve the effectiveness of anticancer drugs in cells of the tumor and permit the use of lower doses of anticancer drugs, with reduction in harmful side effects.
Absstract of: WO2024119103A1
Provided herein are lipid nanoparticles (LNPs) comprising a therapeutic nucleic acid (TNA) and uses thereof. The LNPs comprise an ionizable lipid; a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, and do not comprise a helper lipid.
Absstract of: EP4628071A1
The invention discloses a targeted nanoscale particle, a targeted cell, a preparation method therefor, and use thereof. The targeted nanoscale particle is bound to the outer surface of the targeted cell, and is composed of a plurality of proteins interconnected via a first binding site. The targeted nanoscale particle further comprises a second binding site, and is bound to the outer surface of a target cell via the second binding site. In an exemplary embodiment, the targeted nanoscale particle can promote the interaction between the two types of cells by simultaneously binding to a chimeric antigen receptor T cell and a leukemia cell, thereby promoting the recognition and killing of the leukemia cell by the chimeric antigen receptor T cell. In addition, the internal cavities of the proteins in the targeted nanoscale particle provide space for loading of a chemotherapeutic drug, thus realizing the combination therapy of the chimeric antigen receptor T cell and other therapies while loading the drug.
Absstract of: WO2024119098A1
The present disclosure describes compositions, nanoparticles (such as lipid nanoparticles), and/or lipid nanoparticle compositions and methods of their use.
Absstract of: AU2023406321A1
The present disclosure provides novel polymer-conjugated lipids, e.g., comprising DODA conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations.
Absstract of: AU2023406303A1
Provided herein are lipid nanoparticle (LNP) compositions (e.g., pharmaceutical compositions) comprising a therapeutic nucleic acid (TNA), wherein the LNP comprises an ionizable lipid; a "helper" lipid, e.g., a ceramide or distearoylphosphatidylcholine (DSPC); a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, as well as uses thereof.
Absstract of: MX2025006274A
This disclosure provides a bispecific canine antigen-binding molecule comprising a first antigen binding domain or antigen-binding portion thereof that specifically binds canine CD3, and a second antigen binding domain or antigen-binding portion thereof that specifically binds canine CD20, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD3, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD20, compositions comprising the same, and methods of their use.
Absstract of: AU2023401698A1
Provided herein are pharmaceutical compositions comprising surface functionalized carbon nanotube and an active agent. The active agent can be attached to the carbon nanotube covalently or noncovalently. Also provided are methods of preparing the pharmaceutical compositions and methods of use thereof.
Absstract of: EP4628102A2
The drugs available for the treatment of cutaneous leishmaniasis have unsatisfactory efficacy, frequent and serious adverse effects, and require long treatment regimens. Thus, the search for new treatment alternatives for cutaneous leishmaniasis is considered a priority by the World Health Organization. Parenteral administration of pentavalent antimonials for the treatment of all forms of leishmaniasis, including cutaneous leishmaniasis, has several limitations. The therapy is long, requires repeated doses, and adverse reactions are frequent. Topical treatment is an attractive alternative for cutaneous leishmaniasis, offering significant advantages over systemic therapy: fewer adverse effects, ease of administration, and lower costs. The present inventors aimed to provide a fixed-dose topical composition containing at least one antileishmanial compound, providing adequate absorption of the active ingredient. Another objective of the present invention is to provide a topical, fixed-dose formulation containing a combination of antileishmanial compounds that has sufficient efficacy and safety to be used in the treatment of cutaneous leishmaniasis.
Absstract of: EP4628496A1
A steroid-cationic lipid compound as represented by formula (I). The LNP prepared from the compound can deliver a bioactive substance to a target cell or organ in an effective and stable manner, and the mRNA LNP prepared from the compound has good levels of stability and transfection efficiency, and can trigger a relatively high specific antibody response and cellular immune response in an animal.
Absstract of: EP4628494A1
A phosphatidylamine compound including a plurality of tertiary amino group structures and the composition and use thereof are provided. The phosphatidylamine compound is a phospholipid compound including two or more tertiary amino group structures, the structure of which is represented by the following formula (I), where, the definition of each substituent is detailed in the instructions. The compound works together with other lipid components such as cholesterol, DSPC/DOPE, DMG-PEG2000, and other helper lipids to form lipid nanoparticles (LNPs), which may be used for efficient delivery of drug molecules such as nucleic acids (siRNA, mRNA, pDNA), thereby realizing diagnosis and treatment of diseases such as cancer, fibrosis (e.g., liver, lung, kidney).
Absstract of: AU2023406947A1
The present application discloses modified single-stranded DNA molecules, as well as their cell-free methods of synthesis and their use as therapeutic agents.
Absstract of: WO2024119037A1
Provided herein are an ionizable lipid compound, a lipid nanoparticle comprising the ionizable lipid compound, a composition comprising an mRNA formulated in the lipid nanoparticle, and a method of delivering an mRNA to a subject or a cell by administering the composition including an mRNA formulated in the lipid nanoparticle to the subject or cell.
Absstract of: AU2023406947A1
The present application discloses modified single-stranded DNA molecules, as well as their cell-free methods of synthesis and their use as therapeutic agents.
Nº publicación: EP4626408A2 08/10/2025
Applicant:
COLORADO SCHOOL OF MINES [US]
UNIV COLORADO REGENTS [US]
Colorado School Of Mines,
The Regents of the University of Colorado, a body corporate
Absstract of: WO2024118638A2
Embodiments of the present disclosure provide novel compositions and methods for making and using polymer-coated nanocapsules. In certain embodiments, compositions and methods are disclosed for embedding at least one agent in a liquid fatty acid composition to form an inner core of the polymer-coated nanocapsule and coating the at least one agent-containing liquid fatty acid composition inner core with polymer to form at least one coating layer of polymer that further includes at least one positively charged surfactant (e.g., cationic surfactant), forming polymer-coated nanocapsules. In certain embodiments, the at least one positively charged surfactant binds to at least one targeting agent for directed use of the polymer-coated nanocapsules.
BOPI
Electronic site
